TOKYO, Apr 27 (Pulse News Wire) – Astellas Pharma Inc. (4503.T) reported record revenue and core operating profit for fiscal year 2025.
Revenue reached ¥2.1 trillion, up 30.1% year-over-year, driven by strong growth in key strategic products such as PADCEV, IZERVAY, VYLOY, VEOZAH, and XOSPATA. Core operating income surged to ¥600.0 billion, marking a significant increase of 61.2%. The company's cost management initiatives, particularly its Sustainable Margin Transformation (SMT) program, contributed to improved profitability. General and administrative expenses decreased by 2.3 percentage points compared to the previous year, while research and development costs remained stable despite increased investment in late-stage trials.
Looking ahead, Astellas forecasts continued growth in key strategic products and expects to achieve revenue exceeding ¥2.300 billion in fiscal year 2026. The company anticipates core operating income of more than ¥700 billion, with a targeted core operating margin rate of 32%. Key pipeline advancements include upcoming clinical trials for setidegrasib and ASP546C, along with regulatory events for PADCEV. Astellas also plans to enhance shareholder returns through dividend increases, projecting a per-share payout of ¥150 for the next fiscal year.
🔴 Confidence: Review recommended AI-translated content.